home / stock / trpxy / trpxy news
SciSparc Engages Procaps for Development and Production of CannAmide™ and its SCI-110 Product Candidate The companies will work together on next phase of development following successful phase IIa clinical study for Tourette Syndrome in 2018 and preparations for CannAmide...
SciSparc Initiates Commercial Production of its CannAmide™ Pills The Anti-Inflammatory, Chronic Pain Treatment Is Expected to Be Distributed In Pharmacies Across Canada PR Newswire TEL AVIV, Israel , Feb. 9, 2021 /PRNewswire/ -- SciSparc Ltd.(formerly ...
Therapix Biosciences Announces Name Change to SciSparc Ltd. PR Newswire TEL AVIV, Israel , Jan. 28, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatme...
Therapix Biosciences and Cyntar Ventures Entered a Non-Binding Letter of Intent for the Distribution of TheraPEA in Canada Therapix's TheraPEA product has all required Canadian approvals for distribution PR Newswire TEL AVIV, Israel , Jan. 5, 2021 /PRNewswire...
Therapix Biosciences Announces Upgrade to OTCQB Venture Market TEL AVIV, Israel , Dec. 8, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannab...
Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain TEL AVIV, Israel , Dec. 2, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (OTC Pink: TRPXY), a specialty, c...
Therapix Biosciences Issues CEO Letter to its Shareholders PR Newswire TEL AVIV, Israel, Nov. 30, 2020 TEL AVIV, Israel , Nov. 30, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty, clinical-stage pharmaceut...
Therapix Biosciences Announces Pricing of $4.2 Million Offering PR Newswire TEL AVIV, Israel, Nov. 19, 2020 TEL AVIV, Israel , Nov. 19, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (OTC Pink: TRPXY), a specialty, clinical-...
TEL AVIV, Israel , Aug. 21, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today the replacement of its board of directors. The Comp...
News, Short Squeeze, Breakout and More Instantly...
SciSparc Ltd ADR Company Name:
TRPXY Stock Symbol:
OTCMKTS Market:
SciSparc Engages Procaps for Development and Production of CannAmide™ and its SCI-110 Product Candidate The companies will work together on next phase of development following successful phase IIa clinical study for Tourette Syndrome in 2018 and preparations for CannAmide...
SciSparc Initiates Commercial Production of its CannAmide™ Pills The Anti-Inflammatory, Chronic Pain Treatment Is Expected to Be Distributed In Pharmacies Across Canada PR Newswire TEL AVIV, Israel , Feb. 9, 2021 /PRNewswire/ -- SciSparc Ltd.(formerly ...
Therapix Biosciences Announces Name Change to SciSparc Ltd. PR Newswire TEL AVIV, Israel , Jan. 28, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatme...